Sanara MedTech Inc. Announces Second Quarter Earnings Release and Conference Call Dates
Sanara MedTech Inc. (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies for surgical, chronic wound, and skincare markets, has announced the dates for its second quarter 2024 earnings release and conference call. The company will issue its earnings release on Monday, August 12, 2024, followed by a conference call on Tuesday, August 13, 2024, at 9:00 a.m. Eastern Time.
Investors can access the conference call via a toll-free number (888-506-0062 for domestic callers, 973-528-0011 for international callers) using the access code 984768. A telephonic replay will be available until August 27, 2024. Additionally, a live webcast of the call will be accessible on the company's website under the Investor Relations section, with a one-year online replay available after the broadcast.
Sanara MedTech Inc. (NASDAQ: SMTI), un'azienda di tecnologia medica focalizzata nello sviluppo e nella commercializzazione di tecnologie trasformative per i mercati della chirurgia, delle ferite croniche e della cura della pelle, ha annunciato le date per la pubblicazione dei risultati del secondo trimestre 2024 e per la conferenza telefonica. L'azienda rilascerà i propri risultati lunedì 12 agosto 2024, seguito da una conferenza telefonica martedì 13 agosto 2024, alle 9:00 ora orientale.
Gli investitori possono accedere alla conferenza telefonica tramite un numero verde (888-506-0062 per i chiamanti nazionali, 973-528-0011 per i chiamanti internazionali) utilizzando il codice di accesso 984768. Una registrazione telefonica sarà disponibile fino al 27 agosto 2024. Inoltre, una trasmissione in diretta della conferenza sarà accessibile sul sito web dell'azienda nella sezione Relazioni con gli Investitori, con una registrazione online disponibile per un anno dopo la trasmissione.
Sanara MedTech Inc. (NASDAQ: SMTI), una empresa de tecnología médica centrada en el desarrollo y comercialización de tecnologías transformadoras para los mercados quirúrgico, de heridas crónicas y de cuidado de la piel, ha anunciado las fechas para la publicación de sus ganancias del segundo trimestre de 2024 y la llamada de conferencia. La empresa emitirá su informe de ganancias el lunes 12 de agosto de 2024, seguido de una llamada de conferencia el martes 13 de agosto de 2024 a las 9:00 a.m. Hora del Este.
Los inversores pueden acceder a la llamada de conferencia a través de un número gratuito (888-506-0062 para llamadas nacionales, 973-528-0011 para llamadas internacionales) usando el código de acceso 984768. Una repetición telefónica estará disponible hasta el 27 de agosto de 2024. Además, una transmisión en vivo de la llamada estará accesible en el sitio web de la empresa en la sección de Relaciones con Inversores, con una repetición en línea disponible durante un año después de la transmisión.
Sanara MedTech Inc. (NASDAQ: SMTI)는 외과, 만성 상처 및 피부 관리 시장을 위한 혁신적인 기술의 개발 및 상용화에 집중하는 의료 기술 회사로, 2024년 2분기 실적 발표 및 전화 회의 일정을 발표했습니다. 회사는 2024년 8월 12일 월요일에 실적 발표를 할 예정입니다, 그 뒤를 이어 2024년 8월 13일 화요일 오전 9시 (동부 시간)에 전화 회의가 진행됩니다.
투자자들은 무료 전화번호(국내 전화 888-506-0062, 국제 전화 973-528-0011)를 통해 회의에 접속할 수 있으며, 접근 코드 984768을 사용해야 합니다. 통화의 다시 듣기는 2024년 8월 27일까지 가능하며, 또한 회사 웹사이트의 투자자 관계 섹션에서 생중계가 가능하고 방송 후 1년 동안 온라인 다시 듣기를 이용할 수 있습니다.
Sanara MedTech Inc. (NASDAQ: SMTI), une entreprise de technologie médicale axée sur le développement et la commercialisation de technologies transformantes pour les marchés de la chirurgie, des plaies chroniques et des soins de la peau, a annoncé les dates de publication de ses résultats du deuxième trimestre 2024 et de la conférence téléphonique. L'entreprise publiera ses résultats le lundi 12 août 2024, suivis d'une conférence téléphonique le mardi 13 août 2024 à 9h00 heure de l'Est.
Les investisseurs peuvent accéder à la conférence téléphonique par un numéro gratuit (888-506-0062 pour les appelants nationaux, 973-528-0011 pour les appelants internationaux) en utilisant le code d'accès 984768. Une répétition téléphonique sera disponible jusqu'au 27 août 2024. De plus, un webinaire en direct de l'appel sera accessible sur le site web de l'entreprise dans la section Relations Investisseurs, avec une rediffusion en ligne disponible pendant un an après la diffusion.
Sanara MedTech Inc. (NASDAQ: SMTI), ein Unternehmen für Medizintechnik, das sich auf die Entwicklung und Vermarktung von transformierenden Technologien für die chirurgischen, chronischen Wunden und Hautpflege-Märkte konzentriert, hat die Termine für die Veröffentlichung seiner Ergebnisse des zweiten Quartals 2024 und die Telefonkonferenz bekannt gegeben. Das Unternehmen wird am Montag, den 12. August 2024, seine Ergebnisse veröffentlichen, gefolgt von einer Telefonkonferenz am Dienstag, den 13. August 2024, um 9:00 Uhr Eastern Time.
Investoren können über eine gebührenfreie Nummer (888-506-0062 für inländische Anrufer, 973-528-0011 für internationale Anrufer) an der Telefonkonferenz teilnehmen, indem sie den Zugangscode 984768 verwenden. Eine telefonische Wiederholung wird bis zum 27. August 2024 verfügbar sein. Darüber hinaus wird eine Live-Webcast der Konferenz auf der Unternehmenswebsite im Bereich Investor Relations zugänglich sein, mit einer einjährigen Online-Wiederholung nach der Übertragung.
- None.
- None.
FORT WORTH, TX, July 30, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced details for the release of its results for the quarter ended June 30, 2024.
Sanara will issue its earnings release on Monday, August 12, 2024, and will host a conference call on Tuesday, August 13, 2024, at 9:00 a.m. Eastern Time. The toll-free number to call for this teleconference is 888-506-0062 (international callers: 973-528-0011) and the access code is 984768. A telephonic replay of the conference call will be available through Tuesday, August 27, 2024, by dialing 877-481-4010 (international callers: 919-882-2331) and entering the replay passcode: 50973.
A live webcast of Sanara’s conference call will be available under the Investor Relations section of the Company's website, www.SanaraMedTech.com. A one-year online replay will be available after the conclusion of the live broadcast.
About Sanara MedTech Inc.
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. The Company markets, distributes and develops surgical, wound and skincare products for use by physicians and clinicians in hospitals, clinics and all post-acute care settings and offers wound care and dermatology virtual consultation services via telemedicine. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX® Surgical Activated Collagen, FORTIFY TRG® Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN™ Verified Inductive Bone Matrix, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix, TEXAGEN® Amniotic Membrane Allograft, and BIASURGE® Advanced Surgical Solution to the surgical market. In addition, the following products are sold in the wound care market: BIAKŌS® Antimicrobial Skin and Wound Cleanser, BIAKŌS® Antimicrobial Wound Gel, and BIAKŌS® Antimicrobial Skin and Wound Irrigation Solution. Sanara’s pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement and cell compatible substrates. The Company believes it has the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost.
Information about Forward-Looking Statements
The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continue,” “could,” “estimates,” “expects,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “target,” “will,” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding our business strategy and mission, the development of new products, the timing of commercialization of our products and the regulatory approval process. These items involve risks, contingencies and uncertainties such as uncertainties associated with the development and process for obtaining regulatory approval for new products, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.
All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.
Investor Contact:
Callon Nichols, Director of Investor Relations
713-826-0524
CNichols@sanaramedtech.com
SOURCE: Sanara MedTech Inc.
FAQ
When will Sanara MedTech Inc. (SMTI) release its Q2 2024 earnings?
What is the date and time for Sanara MedTech's (SMTI) Q2 2024 earnings conference call?
How can investors access Sanara MedTech's (SMTI) Q2 2024 earnings call?
Until what date will the replay of Sanara MedTech's (SMTI) Q2 2024 earnings call be available?
